EDP Sciences logo
Submit your paper
Search
Menu
All issues Volume 40 / No 2 (June 2008) J Extra Corpor Technol, 40 2 (2008) 89-93 References
Free Access
Issue
J Extra Corpor Technol
Volume 40, Number 2, June 2008
Page(s) 89 - 93
DOI https://doi.org/10.1051/ject/200840089
Published online 15 June 2008
  1. Herwaldt LA, Swartzendruber SK, Edmond MB, et al. The epidemiology of hemorrhage related to cardiothoracic operations. Infect Control Hosp Epidemiol. 1998;19:6–8. [Google Scholar]
  2. Karkouti K, Wijeysundera DN, Yau TM, et al. The independent association of massive blood loss with mortality in cardiac surgery. Transfusion. 2004;44:1453–62. [CrossRef] [Google Scholar]
  3. Bishop CV, Renwick WE, Hogan C, et al. Recombinant activated factor VII: treating postoperative hemorrhage in cardiac surgery. Ann Thorac Surg. 2006;81:875–9. [CrossRef] [Google Scholar]
  4. von Heymann C, Redlich U, Jain U, et al. Recombinant activated factor VII for refractory bleeding after cardiac surgery—a retrospective analysis of safety and efficacy. Crit Care Med. 2005;33:2241–6. [CrossRef] [PubMed] [Google Scholar]
  5. Diprose P, Herbertson MJ, O’shaughnessy D, Gill RS. Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study. Br J Anaesth. 2005;95:596–602. [CrossRef] [Google Scholar]
  6. Raivio P, Suojaranta-Ylinen R, Kuitunen AH. Recombinant factor VIIa in the treatment of postoperative hemorrhage after cardiac surgery. Ann Thorac Surg. 2005;80:66–71. [CrossRef] [Google Scholar]
  7. Gowers CJ, Parr MJ. Recombinant activated factor VIIa use in massive transfusion and coagulopathy unresponsive to conventional therapy. Anaesth Intensive Care. 2005;33:196–200. [CrossRef] [PubMed] [Google Scholar]
  8. Hyllner M, Houltz E, Jeppsson A. Recombinant activated factor VII in the management of life-threatening bleeding in cardiac surgery. Eur J Cardiothorac Surg. 2005;28:254–8. [CrossRef] [Google Scholar]
  9. Novo Nordisk, NovoSeven Coagulation Factor VIIa (Recombinant) Package Insert. Bagsvaerd, Denmark: Novo Nordisk; 1999. [Google Scholar]
  10. Kalweit G, Bach J, Huwer H, Winning J, Hellstern P. The impact of cardiac ischemia and reperfusion on markers of activated haemostasis and fibrinolysis during cardiopulmonary bypass: comparison of plasma levels in arterial and coronary venous blood. Thromb Res. 2005;116:33–9. [CrossRef] [Google Scholar]
  11. Bull BS, Hay K, Razzouk AJ, Huse WM. Reinfusion of aspirated pericardial blood during CPB. Part II. Laparotomy sponges are hazardous parts of the CPB circuit? Blood Cells Mol Dis. 2005;34:144–50. [CrossRef] [Google Scholar]
  12. Higgins TL, Estafanous FG, Loop FD, et al. Stratification of morbidity and mortality outcome by preoperative risk factors in coronary artery bypass patients. a clinical severity score. JAMA. 1992;268:1860. [Google Scholar]
  13. Dial S, Delabays E, Albert M, et al. Hemodilution and surgical hemostasis contribute significantly to transfusion requirements in patients undergoing coronary artery bypass. Thorac Cardiovasc Surg. 2005;130:654–61. [Google Scholar]
  14. Koster A, Bottcher W, Merkel F, Hetzer R, Kuppe H. The more closed the bypass system the better: a pilot study on the effects of reduction of cardiotomy suction and passive venting on hemostatic activation during on-pump coronary artery bypass grafting. Perfusion. 2005;20:285–8. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.